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ORIGINAL ARTICLE
Effect of vaccination on the use of antimicrobial agents: a systematic
literature review
T. Mark Dohertya , William P. Hausdorffb,c and Karl G. Kristinssond,e
aGlobal Medical Affairs, GSK, Wavre, Belgium; bPATH, Washington, DC, USA; cFaculty of Medicine, Universite Libre de Bruxelles,
Brussels, Belgium; dDepartment of Clinical Microbiology, Landspitali University Hospital, Reykjavık, Iceland; eFaculty of Medicine,
University of Iceland, Reykjavık, Iceland
ABSTRACT
Background: Antimicrobial resistance is a growing global health threat. To preserve the effect-
iveness of antimicrobials, it is important to reduce demand for antimicrobials.
Objectives: The objective of the study was to screen the existing peer-reviewed literature to
identify articles that addressed the potential impact of influenza or Pneumococcus vaccination
on antibiotic usage.
Data sources: PubMed, Embase
Study eligibility criteria: Clinical studies where antimicrobial prescribing was assessed in both
vaccinated and unvaccinated populations.
Participants and interventions: All patient populations were included (infants, children, adults
and elderly), where the effects of the intervention (vaccination) was assessed
Results: We identified unique 3638 publications, of which 26 were judged to be of sufficiently
high quality to allow the calculation of the potential impact of vaccination. Of these studies 23/
26 found a significant reduction in antibiotic use by at least one of the parameters assessed.
Limitations: Different measures used to define anti-microbial use, studies typically focus on spe-
cific risk groups and most studies are from high-income countries.
Conclusions and implications of key findings: Despite the limitations of the review, the evi-
dence indicates that improved coverage with existing vaccines may significantly reduce anti-
microbial demand. This suggests it may be a valuable tool for antimicrobial stewardship.
KEY MESSAGES
 While vaccines against a number of pathogens have been studied for their ability to reduce
antimicrobial use, currently only vaccination against influenza or pneumococcus has gener-
ated sufficient data for analysis
 Vaccination against either influenza or pneumococcus significantly reduced overall antimicro-
bial prescribing rates, both in vaccinated individuals and at a population level
 Maintaining and expanding vaccination coverage thus appears to be a key tool for antimicro-
bial stewardship
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Alongside the provision of clean drinking water and
vaccination, antimicrobials stand as one of the most
important health interventions of the last two centu-
ries and have helped dramatically reduce both mor-
bidity and mortality from infectious disease [1]. The
prospect of reduced effectiveness of antimicrobial
treatment due to the spread of pathogens resistant to
most antimicrobial agents (AMR) is therefore of great
concern [2]. This is not a new problem: the problem
of evolving AMR was discussed in detail by Falkow
over 40 years ago [3]. However, an increasing number
of reports bears witness to a steep increase in the
prevalence of AMR, both in terms of the number of
different pathogens affected, in the proportion of AMR
isolates and the emergence of strains resistant to
treatment with almost all existing antimicrobials [4].
There are already reports of strains which are essen-
tially untreatable by existing programmes or nearly
incurable with any antimicrobial, moving this issue
from academic debate to burgeoning medical
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emergency [5,6]. Multiple reviews from groups as
diverse as the World Health organization (WHO), the
World Bank, the UK government, the European
Commission and the European Centre for Disease
Prevention and Control (ECDC), have produced a con-
sensus that AMR provides a real and growing threat
to human health. There is also agreement that
improved antimicrobial stewardship (the preservation
of the clinical utility, as far as is possible, of existing
antimicrobials), as well as development of new classes
of antimicrobials, is urgently needed [2,4].
Multiple antimicrobial stewardship activities are
already underway, but these have primarily focussed
on what could be described as curbing inappropriate
exposure to antimicrobials – just a few examples
include reducing or eliminating antimicrobials in
wastewater, reducing use in agriculture, better pre-
scribing guidelines for clinicians and more rapid access
to diagnostic tools to guide prescribing [2]. It is also
understood that use of new antimicrobials should be
restricted, where possible, to prolong their useful clin-
ical life [2]. There is, however one key concept –
discussed by Falkow and other researchers [1,3], but
still often underappreciated by policy-makers and the
public at large – which is that the development of
AMR is a predictable and essentially inevitable out-
come of the use of antimicrobials, even when they are
used responsibly. In many cases, physicians are forced
to initiate treatment with antimicrobials empirically –
i.e. on the basis of symptoms, without diagnostic con-
firmation of the identity or antimicrobial susceptibility
of the presumed pathogen – simply because the con-
sequences of delaying treatment can be severe [2].
Thus, even in well-resourced countries such as the
USA, where diagnostic tools are readily available, it has
been estimated that as many as 67% of all antimicro-
bial prescriptions for respiratory infections are inappro-
priate [7] while a UK analysis suggested that over a
third of all antibiotic prescriptions had no clinical justi-
fication [8]. The same is true for other infections as
well, e.g. for treating diarrheal diseases despite evi-
dence that frequently it may not be clinically appropri-
ate [2]. This overuse of antimicrobials for humans and
animals has serious consequences as some important
pathogens are becoming resistant to the majority of
commonly used antimicrobials (extensively drug-resist-
ant) or even all antimicrobials (pan drug-resist-
ant) [9,10].
While better rapid diagnostics may be able to
reduce inappropriate antimicrobial prescribing in clin-
ical settings, the risk of resistance developing remains,
even where the use of antimicrobials is clinically
justified. As a simple example, multiple countries have
reported an increasing proportion of AMR isolates
from patients diagnosed with acute otitis media
(AOM) [11]. This is particularly problematic, since anti-
microbials are the primary tool for treatment of AOM,
and widespread, albeit appropriate, use of b-lactam
antibiotics for AOM is thought to have contributed to
the development of AMR [11]. It is therefore a reason-
able simplification, to say that any use of antimicro-
bials may potentially contribute to the emergence of
AMR. Reducing the incidence of symptomatic disease
requiring antimicrobial treatment – for example, by
vaccination – can play a role in reducing antimicrobial
use and thus, by implication, retard the development
of AMR. However, for authorities to integrate vaccin-
ation into their plans to reduce the spread of AMR
pathogens, a better oversight of the costs and benefits
is needed which may be hindered by the current lack
of reliable data on which to base concrete policy rec-
ommendations [2]. This systematic literature review
therefore attempts to assess current data on the
impact of vaccination on antimicrobial usage and pro-
vide an estimate of what could be achieved by
improving vaccine coverage.
1.1. Objectives
The objective of this study was to screen the existing
literature to assess the effect of vaccination on the
use of antimicrobial agents. While a broader screening
strategy was initially trialled, the current analysis
focuses on vaccination against influenza and pneumo-
coccus, the only two vaccines for which a significant
body of data is currently available.
2. Materials and methods
2.1. Selection criteria
Since no listings of prior systematic reviews on this
topic could be identified using Cochrane’s PROSPERO
tool when the review was initiated, no existing review
protocol number is reported here. The authors there-
fore developed the protocol with the collaboration of
Pallas health research and consultancy (www.pallashrc.
com) before conducting the literature search. Before
completing the full analysis presented in this review,
initial search strategies were tested on PubMed, and
these did not include a restriction on pathogens (PICO
Intervention parameter, Search string #2, shown
below). This initial screening indicated a number
of vaccine-preventable infections (for example,
Haemophilus influenzae, measles and rotavirus) for
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which potentially relevant studies have been pub-
lished. However, with the exception of influenza and
pneumococcal vaccination, only 1 or 2 studies were
identified, rendering a systematic analysis of those
vaccines essentially meaningless. Therefore, the ana-
lysis was restricted to influenza and pneumococcal
vaccination, for which a substantial number of studies
have been published. In addition, it was noted in the
initial screening searches restricted to broad antimicro-
bial terms such “antibiotic” did not always identify
publications where specific antimicrobials were
studied. Therefore, specific terms for antimicrobials
prescribed for infections associated with influenza or
pneumococcal were included in the search strategy.
Finally, since the objective was to analyse clinical data
with the goal of supporting healthcare-related deci-
sion-making, animal studies were excluded. The ana-
lysis covers publications in the period 01 January 2000
to 01 October 2018, and was restricted to publications
in English, French, Dutch, Danish and Icelandic, so that
original content could be directly assessed by the
authors. The search covered both Medline (accessed
via PubMed) and Embase, returning 2710 hits and
3340 hits respectively.
2.2. Search strategy
Search categories and PICO headings
 Population (Human, all, dates, 01 January 2000 to
01 October 2018)
 Intervention (Vaccination against pneumococcus
and/or influenza)
 Comparison (Vaccinated/Unvaccinated study
populations)
 Outcomes (Antimicrobial use, any methodology).




pneumococc[tiab] OR influenza[tiab] OR flu[tiab]
#3 antimicrobials
antibiotic[tiab] OR antimicrobial[tiab] OR amino-
glycoside[tiab] OR amoxicillin[tiab] OR ampicil-
lin[tiab] OR azithromycin[tiab] OR b-lactam[tiab]
OR carbapenem[tiab] OR cefotaxime[tiab] OR ceftriax-
one[tiab] OR cephalosporin[tiab] OR chlorampheni-
col[tiab] OR ciprofloxacin[tiab] OR clavulan[tiab] OR
clindamycin[tiab] OR cotrimoxazole[tiab] OR co-trimox-
azole[tiab] OR erythromycin[tiab] OR fluoroquinolo-
ne[tiab] OR gentamicin[tiab] OR gentamycin
[tiab] OR penicillin[tiab] OR piperacillin[tiab]
OR quinolone[tiab] OR streptomycin[tiab] OR
sulfamethoxazole[tiab] OR tetracyclin[tiab] OR
trimethoprim[tiab]
#4 animal studies
animals[Mesh] NOT (humans[Mesh] AND
animals[Mesh])
The search strategy for PubMed was (#1 AND #2
AND #3) NOT #4, while for Embase it was (#1 AND #2
AND #3)
2.3. Selection of articles
To reduce as much as possible any selection or publi-
cation bias, the articles to be reviewed were identified
by a two-step selection protocol devised by an inde-
pendent health research and consulting company,
Pallas (www.pallashrc.com), commissioned specifically
for the task by GSK (Figure 1). First, articles were
retrieved from the PubMed and Embase databases.
Then, after removal of duplicates and screening for
relevance (see the PICO headings above), the retrieved
articles were assessed using CONSORT guidelines to
ensure all studies included were considered standards-
compliant. The full list was screened based on title
and abstract yielding potentially relevant articles to be
assessed on the basis of their full text. The selection
criteria were finalized prior to screening of articles.
Articles were considered relevant if they discussed
clinical studies where antimicrobial prescribing was
assessed in both vaccinated and unvaccinated popula-
tions, either side by side or chronologically. All patient
populations were included (infants, children, adults
and elderly), and study designs included randomized
controlled trials (RCTs), observational studies, and
population-based database studies.
The exclusion criteria were that a study did not
address the review objective, that it was not a primary
epidemiologic or clinical study (case series, case
reports, review articles and editorials were considered
out of scope) or it represented a report in the so-
called “Grey literature” such as meeting abstracts, let-
ters, websites, etc. (Figure 1).
In the second selection step (also performed by
Pallas), the full text articles selected in step 1 were
assessed using two additional exclusion criteria. These
were that the methods section did not provide suffi-
cient details to fully assess the study population or
methodology, or that no quantitative data could be
retrieved from the article. As the goal was to assess the
relationship between vaccination and antimicrobial use,
six articles discussing antimicrobial use in a time period
where vaccination was introduced, but which did not
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provide data on uptake of the vaccine or vaccination
coverage data, were also excluded, since this rendered
it impossible to quantitatively assess the impact of vac-
cination. While this (and the exclusion of the grey lit-
erature) raises the issue of incomplete retrieval of
identified research, the inability of this material to pro-
vide quantitative insight into the question posed in the
initial protocol means that they could not contribute to
addressing this question, as published.
2.4. Risk of bias and quality of the study evidence
The analysis employed the methodology checklists
from the Scottish Intercollegiate Guidelines Network
(SIGN) [12]. The SIGN checklists include the criteria on
publication quality and reference the PRISMA, STROBE
and CONSORT guidelines. The PRISMA guideline is
useful for critical appraisal of published systematic
reviews, although it is a guideline for publication
rather than a quality assessment instrument to gauge
the quality of a systematic review and is not used for
assessment of included studies. In a similar vein, the
STROBE statement for observational studies provides a
checklist for publication structures, including potential
quality criteria, while the CONSORT statement includes
a checklist of items that must be reported in papers
describing RCTs in order to be considered compliant.
The SIGN checklists (see Supplementary material 1)
were used to identify publications with potential
reporting or critical quality issues. For this, the prede-
fined aspects of a study were qualitatively reviewed
for each publication by checking compliance of the
methodology against a checklist for each specific
study design and assigning a response of “Yes”, “No”,
“Cannot be determined” or “Not Applicable” to each
question. At the end of this process, the evaluator
rated the overall quality assessment of a study. There
are four possible categories of study quality:
 High quality (þþ): When the majority of the criteria/
questions in the SIGN checklist are met, the quality
of the study is rated as high (þþ), which means
Figure 1. CONSORT diagram.
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that there is little or no risk of bias, and the results
are unlikely to be changed by further research.
 Acceptable (þ): Most criteria/questions in the SIGN
checklist are met then the quality of the study is
scored as acceptable (þ), which means that some
flaws in the study may be present with an associ-
ated risk of bias, and the study conclusions may
change in the light of further studies.
 Low quality (): Most criteria are not met, the
study quality is rated as low () which means that
there may be significant flaws to key aspects of the
study design, and further research is very likely to
change the study conclusions.
 Unacceptable – reject (0): The study quality is
unacceptable and therefore the study was excluded.
The final decision whether the quality of a study
was sufficient for inclusion was based on the expertise
of the Pallas epidemiologists involved, based on the
results of the SIGN checklist and the objectives of the
review in mind. In case of doubt, studies were dis-
cussed with a second or third epidemiologist.
There is no SIGN checklist available for, or suitable for,
scoring population-based database studies, so the
ROBINS-I methodology was applied to these to these
studies. The outcome in all cases was: “No information
on which to base a judgement about risk of bias” based
on the finding “There is no clear indication that the study
is at serious or critical risk of bias and there is a lack of
information in one or more key domains of bias (a judge-
ment is required for this).” Therefore, it was decided to
screen included studies for specific limitations, relevant
for the purposes of this review, and include study details
in the evidence tables (see Supplementary Materials 2).
The following questions were asked:
 Does the study compare multiple years before and
after introduction of the vaccine?
 Is there a link on individual level between vaccin-
ation data and antimicrobial use?
 Is the study large enough to have sufficient power?
 Is vaccination coverage data available for the popu-
lation under investigation?
No studies were excluded based on this analysis.
2.5. Quality control
The following quality control measures were applied:
 All titles and abstracts were screened independ-
ently by two researchers from Pallas. The results
were compared and discussed.
 All full text articles were critically appraised inde-
pendently by two researchers from Pallas. The
results were compared and discussed early in
the process.
 Data extraction: the evidence tables were compiled
by one senior researcher and checked by another
senior researcher from Pallas. The selection was
provided as a separate document, which was inde-
pendently re-reviewed by all three authors
 Validation: all full-text articles were read independ-
ently by two of the authors (each paper was
assigned randomly to two of the three authors of
this manuscript), and compared against the com-
piled evidence tables provided by Pallas to ensure
accuracy. A short summary was drawn up by each
author in advance of a meeting where the articles
and data tables were discussed in plenum. Any dis-
agreement between two authors was adjudicated
by the third.
3. Results
Of the 3638 potential articles identified after screening
of the Medline and Embase databases and the elimin-
ation of duplicate entries, 93 were assessed as being
of potential relevance based on title and abstract. The
full text of these were therefore reviewed. Based on
the procedures discussed in the methodology section,
30 articles were identified as potentially relevant for
inclusion in this analysis. The RCTs and non-random-
ized studies were critically appraised using the SIGN
checklists (Supplementary material 1). As there is no
SIGN checklist for scoring population-based database
studies, these were evaluated on study-specific limita-
tions most relevant for the purposes of this literature
review (as described in the methodology section).
Four articles were excluded because of a low SIGN
score and/or limited description of the study charac-
teristics, which made quantitative assessment prob-
lematic [13–16]. The procedure and exclusion criteria
are detailed in the flowchart in Figure 1 and the publi-
cations included for full analysis are presented in
Table 1, broken down by study design and quality
assessment. Study design, study population character-
istics and the vaccines used in all studies included in
this review are also detailed in Supplementary material
2. Extracted data were grouped by study type and
quality and presented in the data tables, without fur-
ther synthesis, meta-analysis or subgroup analysis. A
simple narrative summary is presented in
the Discussion.
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3.1. Influenza vaccination
Of the studies included, 11 presented data on influ-
enza vaccination and antimicrobial use. The readout in
the studies was varied, with antimicrobial use pre-
sented as number of antimicrobial prescriptions,
courses or administration, number of days of oral anti-
microbials, number of days of injected antimicrobials
or whether patients had received antimicrobials. Four
studies described antimicrobial use in children
[17,23,27,34], one in mother-infant pairs and their
household contacts [21], four in adults [28–30,32], one
reported results from a population-level study compar-
ing universal and targeted vaccination policies [31],
and one in household contacts of vaccinated chil-
dren [24].
The four studies examining antimicrobial use in vac-
cinated children (summarized in Table 2) varied signifi-
cantly in quality, as assessed by SIGN guidelines. One
RCT found a more substantial decrease (44%) in anti-
microbial prescriptions among vaccinated children and
their household contacts than the other studies. This
may reflect the fact that the study was conducted in
younger children with recurrent respiratory tract infec-
tions (who comprise a high-risk group for antimicro-
bial prescribing), the fact that the study was also able
to assess the indirect effect of vaccination on other
family members by preventing transmission, or both.
Of the remaining three studies in children, reductions
of 12.6% to 18.6% was reported, though in one of
these studies (Salleras et al.) the reduction was not
significant after adjustment by logistic regression ana-
lysis (Table 2). In the two RCTs, the children received
two doses of vaccine, and in the other two studies,
children received a single vaccination, with only a
few exceptions.
Of the studies that reported on influenza vaccin-
ation and antimicrobial use in adults, one study from
Japan described the number of antibiotic days in older
individuals [28], two studies described antimicrobial
use in adult pilgrims to the Hajj [29,32] and one study
described antimicrobial use in U.S. students [30].
These studies are summarized in Table 3. In the study
conducted by Hara et al. in elderly patients hospital-
ized in the long-term care unit of a Japanese hospital,
influenza vaccination reduced the number of days of
parenteral antimicrobial use (66% reduction), but for
oral antimicrobials the 44% reduction observed was
non-significant when looking at the study population
as a whole, with a more marked reduction in bed-
bound patients who can reasonably be assumed to be
more frail [28]. Both studies of effectiveness of influ-
enza vaccination in Hajj pilgrims – originating from
Malaysia or Pakistan found significant reductions in
antimicrobial use of 41% and 66% respectively [29,32].
A similar reduction of 46% (after adjustment) in anti-
microbial use associated with influenza-like illness was
reported among full-time students attending a U.S.-
based college and university [30].
Three studies, summarized in Table 4, looked at the
effect of influenza vaccination of either children or
adults on antimicrobial use among household mem-
bers. In an Italian study, influenza vaccination of
infants with a history of recurrent respiratory tract
infections was associated with a reduction of 27% and
33% in antimicrobial prescriptions for their parents
and siblings, respectively [17]. In a placebo-controlled
study of vaccination among children attending U.S.
Navy-affiliated day care centres, a dramatic reduction
(88%) in the number of antimicrobial prescriptions for
their household contacts 5–17 years old was observed
[24]. However, there was no significant effect on pre-
scribing for adult household members or siblings
younger than 5 years [24]. An evaluation of the effect-
iveness of vaccination of other family members to pre-
vent influenza in infants (the so-called “cocooning”
strategy) found that postpartum influenza vaccination
of mothers – but not other household members – was
associated with significantly less (45.4% reduction)
antimicrobial administration in infants [21].
Finally, a slightly different approach was described
in an ecological study by Kwong and colleagues of
influenza-associated respiratory antimicrobial prescrip-
tions before and after universal immunization against
influenza was introduced in Ontario. The study found
a reduction (after adjustment) of 64% (95% CI
51%–74%), when comparing rates in Ontario to other
provinces that targeted vaccination only to at-risk
groups [31]. While the magnitude of the observed
reduction is comparable to that reported in the adult
Table 1. Studies included in the final analysis.
Study quality (SIGN) Randomized controlled trials Non-randomized studies Population-based database studies
High quality (þþ) [17–20] [21,22]
Acceptable quality (þ) [23–26] [27–31]
Low quality () [32,33]
Not possible to assess with SIGN (o) [34–42]
SIGN: Scottish Intercollegiate Guidelines Network.
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vaccination studies analysed here, the different study
design makes direct comparison problematic.
3.2. Pneumococcal vaccination
Of the studies included in this analysis, the vast major-
ity (12/13) analysed vaccination and antimicrobial use
in children [18,19,22,25,26,35–41]; the remaining article
reported on antimicrobial use in all age groups,
though the greatest effects were seen in children [42].
This reflects the fact that unlike influenza, pneumococ-
cal conjugated vaccines (PCVs) are primarily recom-
mended for use in children. As was the case for the
influenza-related studies discussed above, study end-
points differed, with antimicrobial use variously pre-
sented as whether or not antimicrobial treatment was
used, number of antimicrobial courses, prescriptions,
courses, or purchases per patient, or as antimicrobial-
days for upper respiratory infections (URIs), lower
respiratory infections (LRIs) and/or otitis media (OM).
Studies in children which could be assigned a SIGN
score (RCTs and a prospective cohort study) are sum-
marized in Table 5, while the results from observa-
tional studies are summarized in Table 6. An
additional complicating factor is the fact that while
seasonal influenza vaccines are all based on the same
antigens, selected in advance for that season’s pre-
dicted dominant strains, there are several PCVs on the
market [43]. Although clinical data suggest the most
commonly used vaccines have similar effectiveness
with regard to overall prevention of pneumococcal
disease, this remains a potential source of difference
between studies [43]. For the studies reported here,
nine reported results that included the 7-valent PCV7
vaccine, five reported results that included the 10-val-
ent pneumococcal Haemophilus influenzae protein D
conjugate vaccine (PHiD-CV10), five reported results
that included the 13-valent PCV13 vaccine, one from
the experimental 9-valent PCV9 vaccine and one from
the 23-valent non-conjugated vaccine. The sum of
these numbers are greater than the total number of
studies included in this analysis, because several stud-
ies reported results spanning periods where different
pneumococcal vaccines were in use. Finally, the dur-
ation of follow-up varied widely in studies of the
impact of pneumococcal vaccination. In studies where
both influenza and pneumococcal vaccines were
assessed simultaneously, or in clinical trials of
pneumococcal vaccination, the follow-up period at
1–3 years was comparable to that of the influenza tri-
als. However, the population cohort studies for
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period before and after vaccination introduction, lead-
ing to data accumulation over 5–14 years, which may
hamper the assessment of the impact of pneumococ-
cal vaccination on antibiotic use, given the downward
trend driven by guideline changes [35,42].
All of the RCTs and prospective studies included
were considered at low or moderate risk of bias and
the results for the pneumococcus-vaccinated cohorts
as a whole suggest a significant overall reduction in
antimicrobial prescribing in the range of 5–17% (Table
5 and [18,19,22,25,26,40]). However, while the sub-
analyses showed a clear trend towards significant
reduction of antimicrobial use in vaccinated children
and infants, the magnitude of the effect was quite dif-
ferent in different sub-groups. The analysis of PCV9
effect by Dagan and colleagues in Israeli children
attending day-care showed that vaccination reduced
overall antimicrobial days by 17%. This benefit was
attributed to reductions in prescribing for URI
(reduced 10%), OM (reduced 20%) and LRI (reduced
47%). There was no reduction in antimicrobial days for
other illnesses [18]. When stratified for age, children
under 36months of age saw benefits in terms of
reduced antimicrobial use for OM and LRI, while chil-
dren 36months and older saw benefits in terms of
reduced antimicrobial use prescribed for URI and LRI
[18]. Three studies in vaccinated infants, drawing on
populations from Finland, Italy and the USA, using
PCV7 and PHiD-CV10, also found significant reductions
in antimicrobial treatment (Table 5 and [19,22,25]).
Although the endpoints in the three studies are differ-
ent enough that a direct comparison is not possible, it
is safe to say that reduction in prescribing associated
with OM appeared to be one of the major drivers,
consistent with the important role pneumococci play
in the aetiology of this disease.
The final RCT discussed here is significantly differ-
ent in terms of target population to those discussed
above, since it assessed impact of the PHiD-CV10 vac-
cine in children and adolescents under 18 years of age
with recurrent protracted bacterial bronchitis, chronic
suppurative lung disease or bronchiectasis. Although
the vaccinated participants were less likely to have
respiratory symptoms and required fewer short-course
antimicrobial treatments than the control group, this
difference was not significant (incidence density ratio
0.81, 95% confidence interval 0.61, 1.09), possibly
because in this high-risk group, antimicrobial use (also
for unrelated infections) was high throughout the
trial [26].
The remaining studies evaluated here (Table 6) are














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































292 T. M. DOHERTY ET AL.
before and after vaccination [35–37,39–42]. Despite
these similarities, there remain substantial differences
in endpoints, duration of the studies and the vaccines
used, so direct comparisons of the results need to be
approached with caution. That said, certain trends are
immediately discernible. For example, all of the studies
found a significant reduction in the percentage of chil-
dren prescribed antimicrobials after the introduction
of universal childhood vaccination with PCVs (Table 6)
[19,35–37,39–42]. In addition, where this was analysed,
the data suggest that there was a significant reduction
in the percentage of children requiring recurrent anti-
microbial prescriptions, as well as in the volume of
prescribing [35]. As was reported for the trials dis-
cussed and summarized in Tables 5 and 6, significant
reductions in antimicrobial prescribing for OM, pneu-
monia and respiratory tract infections appeared to be
associated with all of the PCVs tested, suggesting that
this is a class effect, consistent with the reduction in
antimicrobial use being driven by reduction in the
incidence of pneumococcal disease. However, the
magnitude of the reported reductions ranged from a
few percent to over 73% (Table 6). It is unlikely that
differences in the precise endpoint can explain this
degree of variation, and instead suggest the influence
of major methodological differences or confounders.
3.3. Combined influenza and pneumococcal
vaccination
Two studies were identified that examined the poten-
tial effect of vaccinating against both influenza and
pneumococcus. One was a double-blind, placebo-con-
trolled RCT in children of 18–72months of age, with a
previous diagnosis of respiratory tract infection, con-
ducted in the Netherlands over two influenza seasons,
with a follow-up period of 18months [20]. The other
was a cohort study from France, drawing on regional
health records of adults 65 years and older [33]. Study
parameters are defined in Table 7. In the RCT in chil-
dren, trivalent influenza vaccine (TIV) or TIVþ PCV7
vaccinations were associated with only non-significant
reductions in the percentage of children receiving an
antimicrobial prescription. There were also no signifi-
cant differences between children receiving influenza
vaccination plus placebo, versus influenza vaccination
plus PCV7. The authors note that results may reflect,
at least in part, the mild influenza seasons in the years
studied, the short (18month) observation period, and
the presence of suboptimally matched H3N2 strain
and influenza B viruses in the 2003–2004 and
2004–2005 influenza seasons, respectively [20].
The observational study in older adults, conducted
over two influenza seasons in France, compared
results in older adults who had been offered influenza
vaccination and pneumococcal vaccination (the 23-val-
ent pneumococcal capsular polysaccharide vaccine:
PPV23) as part of a vaccination campaign [33]. Only
62.5% adults received vaccination, and not all those
vaccinated received both vaccines, allowing a compari-
son to be made between cohorts who had received
both, either, or neither vaccine. It should be noted,
however, that a relatively small percentage (5.5%)
received the pneumococcal vaccination alone, making
this arm of the study potentially less robust. Antibiotic
use peaked in all groups immediately after the influ-
enza season in both years studied, suggesting at least
a temporal association, but interestingly, those who
had received both vaccines also had the highest rate
of antimicrobial prescribing, while those who received
neither vaccine also had the lowest rate of antimicro-
bial prescribing. Influenza vaccination (with or without
PPV23) significantly reduced all-cause mortality in this
study, indicating that the vaccine appeared to be
effective, but no reduction in antimicrobial prescribing
was reported. This raises the concern (also noted by
the authors) that there may be a selection bias, pos-
sibly reflecting access to healthcare services or priori-
tization of different groups for vaccination.
4. Discussion
The starting point for this review was the growing
concern over increasing levels of AMR [4–6], and an
interest in what concrete actions might be taken to
improve antimicrobial stewardship at a global level.
One of the starting assumptions was that for any
intervention to be broadly taken up, it needed to be
practical and economically sustainable, and it needed
to be supported by sufficient data to enable its utility
to be assessed. We hypothesized that the use of exist-
ing vaccinations could reduce disease and therefore,
indirectly to reduce antimicrobial prescribing. If this
was correct, vaccination could potentially meet the
first two criteria, but that data describing the potential
magnitude of the effect was not readily accessible,
being scattered across multiple publications, each –
on its own – with limited generalizability. An example
of this is the publication of an analysis of the paediat-
ric pneumococcal vaccination programme in Finland,
which attempted to outline the downstream benefits
of vaccination, which include reduced healthcare util-
ization and reduced antimicrobial prescribing [19].
While the effect is measurable in that case, it is not
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clear if it would apply to other populations or other
settings, a point the authors themselves make [19].
We therefore conducted a systematic review to assess
the potential impact of vaccination on antimicrobial
prescribing.
The studies summarized in this review appear to
confirm the starting hypothesis that vaccination with
trivalent influenza vaccines and conjugated pneumo-
coccal vaccines significantly reduces antimicrobial con-
sumption in the period immediately or shortly after
vaccination. Of the 26 studies retrieved for this ana-
lysis, 23 found significant reductions in antimicrobial
use in vaccinated individuals or groups, and in the
remaining 3, all but one found non-significant reduc-
tions. Further, all of the studies but one rated as being
at low risk of bias using the SIGN scoring method
found significant reductions in antimicrobial use. The
one study considered at low risk of bias, that did not
find a significant difference noted potential epidemio-
logical considerations that may have blunted the
effect of vaccination – specifically a poor match
between the influenza vaccine used and common cir-
culating strains in the influenza seasons during the
study period [20]. Nonetheless, the data strongly sug-
gests that vaccination against either influenza or
pneumococci can reduce overall healthcare visits and
antimicrobial consumption and sharply reduce anti-
microbial prescribing in patients with diagnoses asso-
ciated with otitis media and upper respiratory tract
infections [13–17,34], although the variations in study
design, vaccines used and study populations make it
impossible to provide a single precise estimate of the
impact of vaccinating against influenza or
pneumococci.
However, despite the impossibility of synthesizing a
single figure, some useful observations may be made.
In children, influenza vaccination appeared to reduce
overall antimicrobial consumption by approximately
14.5% (median value, unadjusted), albeit with signifi-
cant variation [23,27,34]. This is a conservative esti-
mate, as it looks only at vaccine effectiveness in the
vaccinated children: household transmission studies
suggest an additional significant benefit from reduced
transmission [17,24]. In adults, a substantially larger
proportional reduction in antimicrobial consumption
after vaccination was seen, with an unadjusted median
of 52% across the studies included in this review. This
may reflect the relatively higher likelihood in adults
(compared to young children) that influenza will pro-
voke symptoms severe enough to cause the infected
individual to seek medical advice (and therefore
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For pneumococcal vaccination, the situation is simi-
lar – there are sharp declines in antimicrobial use
associated with specific diagnoses associated with
pneumococcal infection such as OM, ranging from
21% to 73% [18,19,22,25,26,35–41]. Smaller, but still
significant declines in total antimicrobial prescribing in
the range 2–19% were reported [18,19,22,25,26,35–41].
While this reduction may not seem dramatic, the total
number of prescriptions associated with diagnoses of
pneumococcal infection is such that this could result
in significant savings in antimicrobial utilization – it
has been estimated in one study that one antimicro-
bial prescription is avoided for every 5 children vacci-
nated against pneumococci [19]. That said, however, it
must be acknowledged that there are significant gaps
in the literature, and that any conclusions on the mag-
nitude of the reduction and the general applicability
of these findings must be approached with caution.
This review is subject to several important limita-
tions: the first is that very little published data is avail-
able on vaccines for pathogens other than influenza
or pneumococci, as noted in the methodology section.
Any current analysis therefore, can only hope to give
a partial picture of the potential overall impact of vac-
cination for reducing antimicrobial use.
A second major limitation is that there was no con-
sensus between the reported studies on how anti-
microbial use was measured and reported. The studies
included in this review use different measures, such as
antimicrobial-days, number of prescriptions, or binary
measures such as whether antimicrobials were dis-
pensed or not. Some studies have measured any anti-
microbial, others have analysed by type. The disparity
of measurements used could potentially lead to differ-
ent outcomes and may explain the high degree of
variation reported: for example, a reduction in anti-
microbial-days required may detect a reduction where
a binary analysis of whether any antimicrobial was
used or not, may fail to do so. These differences in
reported outcome prevent the synthesis of the col-
lected data into a single value, and the analysis here
is therefore restricted to indicating the general magni-
tude and range of the impact observed.
The third limitation is that the majority of the pub-
lished studies assessed in the review focus on specific
risk groups, such as infants or older adults with
comorbidities. While the rationale for this is obvious –
these are priority groups for vaccination – it does
mean that our ability to generalize from these results
is limited. Against this limitation however, we can bal-
ance the observation that reductions in antimicrobial
use among at least some of the vaccinated study
populations are reported by the majority (23 out of
26) of the studies included in this review.
One final limitation is that most of the studies
reported here are from high-income countries where
antimicrobial prescribing is relatively strictly controlled.
Access to antimicrobials varies significantly between
countries [2] and it is not clear if quantitatively similar
reductions could be obtained in low- and middle-
income settings, especially those where antimicrobials
are available without a prescription. There is however,
reason to think that this may be the case. Two studies
in Hajj pilgrims, drawing on subjects from Pakistan
and Malaysia, found significant reductions in the use
of antimicrobials, on a scale (41% and 61%, respect-
ively) comparable to that reported in studies from
high income countries [29,32]. Both studies also
reported a reduction of similar magnitude in the dis-
pensing or use of non-prescription remedies [29,32].
These data are therefore consistent with the underly-
ing assumption presented in the introduction, that
reductions in disease (in this case, influenza-like ill-
ness) also result in a reduction in treatment-seeking
generally, and thus, indirectly, in consumption of med-
icines, including antimicrobials. Hypothetically, this
pattern of behaviour should, be generally applicable.
It should be noted, however that these studies were
non-blinded with regard to the participants’ vaccine
status and thus possibly subject to bias with regard to
treatment-seeking or treatment-dispensing behaviour.
While the studies under review that reported dis-
ease incidence all found significant decreases in the
outcome measured, the association of decreased mor-
tality with declines in antimicrobial use did not hold
in every case. In one large observational study in
adults aged 65 and older from France, it was shown
that influenza vaccination was associated with signifi-
cantly reduced mortality in vaccinees, particularly in
those who also received concurrent PPV23 vaccination
[33]. However, no associated reduction in antimicrobial
prescribing was observed. This is particularly puzzling,
since in all groups antimicrobial prescribing rose
through the influenza season, peaking shortly after
the peak of the influenza season and then falling. This
is consistent with the concept that antimicrobials were
being prescribed for patients based on respiratory
infections, but the reduction in mortality is not
reflected in prescribing numbers. The authors of that
study suggest that this may be due to the fact that in
older adults, the effectiveness of the influenza vaccine
against hospitalization and death is generally higher
than its effectiveness at preventing influenza-like ill-
ness, so that vaccinated individuals may still seek
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healthcare, and be prescribed antimicrobials even if
the severity of their illness – and consequently, mortal-
ity – is reduced [33]. It is, however, not possible to
confirm that hypothesis from the data available.
The health status of vaccinees or contacts may
have also confounded results in some studies. In one
U.S. study looking at antimicrobial use within families
with children attending day-care, vaccination against
influenza of the children was associated with reduced
morbidity in unvaccinated siblings, and reduced use
of both antimicrobials and non-prescription medicines
[24]. However, no effect on either aspect was seen on
adult contacts. In contrast, a similar study in Italy
found reduced morbidity and antimicrobial use in
both parents and siblings of vaccinated children [17].
It is possible that this may reflect differences in the
tendency to seek healthcare for child and adult
patients with influenza-like illness, but the authors of
the U.S. study suggested that the lack of effect they
observed in adults may reflect the relatively high pro-
portion of adults in their study population who were
vaccinated against influenza [24]. It may also reflect
the small numbers vaccinated in some age
cohorts [24].
The last limitation that needs to be addressed is
the challenge of attributing changes in antimicrobial
prescribing over time to vaccination. While this is a
less significant issue in RCTs, many of the studies dis-
cussed here are observational studies, some of which
have collated data over extended periods. Changes in
diagnostic criteria or prescribing guidelines following
heightened awareness about the threat of antimicro-
bial resistance [35,42], healthcare seeking patterns,
other diseases, such as the pandemic influenza out-
break [37], availability of specific antimicrobial formu-
lations [35] or even factors that affect disease
incidence, but which are unrelated to vaccination (for
example, a decrease in OM associated with a decrease
in second-hand smoke exposure [36,42,47]) may all
impact antimicrobial use. While this can be controlled
for to some extent, for example by comparing anti-
microbial prescribing rates to specific diagnoses, or to
antimicrobial use for conditions unrelated to the vac-
cine-preventable disease, the risk of unidentified con-
founders cannot be excluded.
Bearing these caveats in mind, data from 9 out of
10 of the influenza vaccination studies reported sig-
nificant reductions in at least one of the measures of
subsequent antimicrobial prescribing used (Tables
2–4). Although there were some outliers, reported vac-
cine effectiveness at reducing antimicrobial prescribing
in different groups tended to be relatively consistent
within age cohorts. The different outcome measures
reported preclude the synthesis of this data into a for-
mal point estimate, but in children, effectiveness of
influenza vaccination (Table 2) showed a median
reduction of 14.5%, range 12.6–44.0%) while in adults
(Table 3) the median reduction was 64%, with a range
of 41–66%. Studies involving both adults and children
reported more variable outcomes (Table 4: median
reduction 33%, range 0–88%, depending on how age
cohorts were stratified). Encouragingly, these conclu-
sions are similar to a very recent systematic review of
vaccination impact on antibiotic use despite the fact
that the two reviews used different inclusion criteria
and reviewed an overlapping, but not identical list of
publications [48].
With regard to pneumococcal vaccination, all but
one of the 13 studies reviewed were conducted in
infants or children and among this group. These stud-
ies are subject to the same caveats regarding diversity
of outcome measures, study parameters, plus an add-
itional caveat regarding the valency of the different
vaccines used, which again precluded the synthesis of
results. Nonetheless, 12 out of 13 studies found a sig-
nificant reduction in antimicrobial use in at least one
of the reporting measures used (Tables 5 and 6). The
median reduction across these different measures was
13.5%, with a range of 1.6–37.1%. The majority of
studies reported reductions in overall prescribing in
the range of 5–20% (Tables 5 and 6) with much higher
percentage reductions in prescribing associated with
acute otitis media. Interestingly, the two studies which
looked at a combination of influenza and pneumococ-
cal vaccination did not show an additional reduction
in antimicrobial use, even though the vaccinations
were clearly effective against both influenza and
pneumococcal-related disease and showed an additive
effect on mortality in older adults (Table 7). This could
reflect the fact that outcomes in both studies were
measured across influenza seasons, which may have
biased the results towards that attributable to influ-
enza-like illness, or it may reflect undetected biases in
healthcare access or patient population as discussed
in the Results section [20].
To conclude, the published data appear to be con-
clusive that vaccination against influenza and
pneumococcal disease has the potential to signifi-
cantly reduce antimicrobial consumption. While this
supports the initial hypothesis we set out to test, it is
still only a partial answer. The lack of studies on the
impact of other vaccines, such as those for rotavirus
or Neisseria meningitidis infections suggests that the
total impact of vaccination may be significantly
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greater than that outlined here, and more research to
clarify this aspect is urgently needed. In addition,
while it is intuitive that reduced antimicrobial use will
translate into reduced antimicrobial resistance, it is
not formally proven that this is the case, although
recent reviews suggest that use of conjugate pneumo-
coccal vaccines reduces carriage and transmission of
resistant pneumococcal strains [49,50] as well as the
effect on total prescribing. If the proportion of second
line antimicrobials used to treat patients is used as
proxy for treatment failure and AMR, then there is
already evidence suggestive of a benefit
[35–37,39–42,51] but in this area too, more research
will be required.
Finally, it must be noted that although the data
appear to strongly support the ability of influenza and
pneumococcal vaccination to reduce overall antimicro-
bial prescribing, there remain significant gaps. In par-
ticular, there is very little data on effectiveness in
older adults, compared to that in infants and children.
Given the high attack rates for both influenza and
pneumococcal disease in this age group, this is a ser-
ious omission. The published literature as reviewed
here is also very heavily biased in favour of studies
from North America and Northern Europe. Whether
the observed reductions can be duplicated in other
settings remain unknown, though the fact that two
studies on influenza from outside this region showed
similar reductions in antimicrobial use is encouraging
[29,32]. Studies to address these questions, as well as
improved health outcome models that include poten-
tial benefits from reduced antimicrobial prescribing
are urgently needed. Nonetheless, these gaps should
not be taken as an excuse for inaction. The existing
data clearly support the initial hypothesis that reduc-
ing symptomatic disease by vaccination against influ-
enza and pneumococcus can also reduce antimicrobial
prescribing. This makes it one of the few tools we
have in hand that has proven effectiveness for anti-
microbial stewardship and one that can be put into
practice today – both factors that should drive health-
care systems to prioritize increasing uptake of
these vaccines.
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